Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 3.3% – Here’s Why

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) fell 3.3% during mid-day trading on Monday . The stock traded as low as $1.45 and last traded at $1.46. 34,640 shares changed hands during trading, a decline of 47% from the average daily volume of 65,132 shares. The stock had previously closed at $1.51.

Wall Street Analyst Weigh In

Several analysts have weighed in on MRKR shares. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.00.

Marker Therapeutics Stock Down 3.3%

The firm has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.52. The company has a market cap of $24.34 million, a P/E ratio of -2.39 and a beta of 1.45.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%. On average, sell-side analysts anticipate that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

Several hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC bought a new position in Marker Therapeutics in the 4th quarter worth approximately $222,000. XTX Topco Ltd lifted its holdings in Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after buying an additional 36,269 shares in the last quarter. Osaic Holdings Inc. boosted its position in Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after buying an additional 13,340 shares during the last quarter. Renaissance Technologies LLC boosted its position in Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after buying an additional 17,400 shares during the last quarter. Finally, LPL Financial LLC increased its stake in shares of Marker Therapeutics by 41.7% in the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after buying an additional 24,500 shares during the period. 22.39% of the stock is owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.